Citigroup Inc Alpine Immune Sciences, Inc. Transaction History

Citigroup Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$17.75 - $41.6 $3.05 Million - $7.14 Million	171,719 Added 479.97%	207,496 $8.23 Million
Q4 2023 Feb 09, 2024	BUY	$8.54 - $20.22 $299,813 - $709,863	35,107 Added 5239.85%	35,777 $681,000
Q3 2023 Nov 09, 2023	SELL	$10.13 - $13.98 $97,308 - $134,291	-9,606 Reduced 93.48%	670 $7,000
Q2 2023 Aug 10, 2023	BUY	$6.84 - $11.91 $66,710 - $116,158	9,753 Added 1864.82%	10,276 $105,000
Q1 2023 May 11, 2023	SELL	$7.0 - $8.75 $497 - $621	-71 Reduced 11.95%	523 $4,000
Q4 2022 Feb 09, 2023	SELL	$5.45 - $7.35 $136 - $183	-25 Reduced 4.04%	594 $4,000
Q3 2022 Nov 10, 2022	SELL	$6.89 - $9.39 $6,738 - $9,183	-978 Reduced 61.24%	619 $4,000
Q2 2022 Aug 10, 2022	BUY	$6.71 - $9.52 $3,717 - $5,274	554 Added 53.12%	1,597 $14,000
Q1 2022 May 12, 2022	SELL	$6.41 - $13.89 $17,454 - $37,822	-2,723 Reduced 72.3%	1,043 $9,000
Q4 2021 Feb 10, 2022	BUY	$10.41 - $13.95 $25,400 - $34,038	2,440 Added 184.01%	3,766 $52,000
Q3 2021 Nov 10, 2021	BUY	$8.19 - $11.31 $10,859 - $14,997	1,326 New	1,326 $14,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.